Today, atai Life Sciences published a heavily anticipated press release discussing the high-level outcomes of its Phase 2a study of PCN-101 (R-ketamine). The proof-of-concept trial, which officially wrapped up on November 10th, 2022, is a significant step in atai’s effort to develop a new, effective, and accessible treatment option for treatment-resistant depression (TRD). The Results In a p ress…
Source